Porcaro Giuseppina, Pavone-Cossut Maria Rosaria, Moretti Sonia, Bilotta Gabriele, Aragona Cesare, Unfer Vittorio
Department of Gynecology and Obstetrics, Women's Health Centre, 05100 Terni, Italy.
National HIV/AIDS Research Center, Istituto Superiore di Sanità, 00161 Rome, Italy.
Int J Mol Sci. 2025 May 29;26(11):5251. doi: 10.3390/ijms26115251.
Human papillomavirus (HPV) infection represents one of the most common sexually transmitted infections worldwide. However, the lack of effective therapeutic strategies to counteract viral infection and its persistence still makes the management of HPV a medical concern. Persistence is indeed a crucial issue in the context of HPV, as it may increase the risk of viral DNA integration into the host genome, thus exposing patients to tumoral progression. This clinical study aims to evaluate the effectiveness of a dietary supplement containing epigallocatechin gallate (EGCG), folic acid (FA), vitamin B12 (B12), and hyaluronic acid (HA) in improving HPV clearance and HPV-induced cervical lesions, and in counteracting viral persistence. A total of 106 patients who tested positive for HPV DNA were enrolled in this study and were treated daily for 6 months with a tablet containing EGCG (200 mg), FA (400 μg), B12 (1 mg), and HA (50 mg) (Pervistop, Lo.Li. Pharma, Rome, Italy). A 6-month treatment with such combined molecules demonstrated a viral clearance in 85.8% of enrolled patients, while 92.3% of participants exhibited no more cervical lesions. Furthermore, 71.8% of patients with persistent infection tested negative to HPV DNA test after 6 months of treatment. The obtained data in this large population strongly support previous evidence on the efficacy of such molecules in the management of HPV infection by improving both viral clearance and related cervical lesions, and by targeting viral persistence.
人乳头瘤病毒（HPV）感染是全球最常见的性传播感染之一。然而，缺乏有效的治疗策略来对抗病毒感染及其持续性，这使得HPV的管理仍然是一个医学难题。在HPV感染的背景下，持续性确实是一个关键问题，因为它可能会增加病毒DNA整合到宿主基因组中的风险，从而使患者面临肿瘤进展的风险。本临床研究旨在评估一种含有表没食子儿茶素没食子酸酯（EGCG）、叶酸（FA）、维生素B12（B12）和透明质酸（HA）的膳食补充剂在提高HPV清除率、改善HPV引起的宫颈病变以及对抗病毒持续性方面的有效性。共有106名HPV DNA检测呈阳性的患者参与了本研究，并每天服用一片含有EGCG（200毫克）、FA（400微克）、B12（1毫克）和HA（50毫克）的片剂（Pervistop，Lo.Li. Pharma，罗马，意大利），持续治疗6个月。用这种组合分子进行6个月的治疗后，85.8%的入组患者实现了病毒清除，而92.3%的参与者宫颈病变消失。此外，71.8%的持续性感染患者在治疗6个月后HPV DNA检测呈阴性。在这一大量人群中获得的数据有力地支持了先前的证据，即这些分子在HPV感染管理中通过提高病毒清除率和相关宫颈病变以及针对病毒持续性方面具有疗效。
